Eli Lilly draws the line on DTC

Share this article:
Eli Lilly is drawing the line on DTC—at the spots plugging the services of ambulance-chasing trial lawyers. The company surveyed 402 shrinks and found that ads by would-be litigators warning of side effects in anti-psychotics are scaring patients off the drugs.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...